Johnson & Johnson is considering a sale of its anti-dandruff shampoo Nizoral as the US health-care giant continues to streamline its portfolio of products, according to people familiar with the matter.
A sale of Nizoral could be valued at a few hundred million dollars and attract other health-care and consumer companies with an interest in over-the-counter treatments, the people said, asking not to be identified because the deliberations are private.
J&J is working with financial advisers on the sale, which is at a preliminary stage, the people said. A spokesman for J&J declined to comment.
Product Review
J&J has been reviewing products ranging from its over-the-counter business to medical devices. Earlier this year, it agreed to sell its blister and lip-care treatment Compeed to HRA Pharma.
It’s also considering a divestiture of its vaginal-mesh surgical product, which could fetch from $500 million to $1 billion, people familiar with the matter have said. J&J is also evaluating options for the diabetes-care business, including a sale, partnership or joint venture.
While the health-care conglomerate has major medical-device and consumer divisions, drugs have been a recent standout. That’s helped J&J outpace many of its large pharmaceutical rivals this year.
After buying Actelion Ltd. for $30 billion this year, Johnson & Johnson has signalled that a new generation of medicines holds the key to its future profits as some of its best-selling drugs begin to lose dominance.
News by Bloomberg, edited by ESM. Click subscribe to sign up to ESM: The European Supermarket Magazine.
